Skip to content
Clinical Trials – home
GreeceBack to Greece

Clinical trials in Cholargos – page 57

1 033 clinical trials in Cholargos, Greece. Every trial is listed in the EU Clinical Trials Register and updated daily.

GreeceOur site in GreeceΚλινικεσΔοκιμεσ.gr(opens in a new tab)
Cholargos at a glance
1 033
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

1 033 trials in Cholargos

Open in trial search

Study of Bemcentinib with Pembrolizumab, Carboplatin, and Pemetrexed for Patients with Advanced or Metastatic Non-Small Cell Lung Cancer with STK11 Mutation

Registered drugNo placebo
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Bemcentinib
  • Sponsor:Bergenbio ASA

Study on Capivasertib and Docetaxel for Treating Metastatic Castration-Resistant Prostate Cancer in Patients

Registered drug
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Capivasertib
  • Sponsor:AstraZeneca AB

Diabetic retinopathy+1

Not recruiting

Study on the Effectiveness and Safety of BAY 3283142 in Reducing Urine Albumin for Patients with Chronic Kidney Disease

Investigational
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:BAY 3283142
  • Sponsor:Bayer AG

Crohn's disease

Not recruiting

Study on the Effectiveness and Safety of Guselkumab for Patients with Fistulizing Perianal Crohn's Disease

Investigational
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Guselkumab
  • Sponsor:Janssen Cilag International

Study on the Effects and Safety of Efgartigimod PH20 SC for Adults with Active Idiopathic Inflammatory Myopathy

Investigational
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Efgartigimod Alfa
  • Sponsor:Argenx

K-ras gene mutation+2

Not recruiting

Study Comparing Divarasib, Sotorasib, and Adagrasib for Patients with Advanced or Metastatic KRAS G12C-Positive Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Sponsor:F. Hoffmann-La Roche AG

Study Comparing Epcoritamab and Lenalidomide with a Drug Combination for Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Registered drugNo placebo
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Epcoritamab
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Study of Acalabrutinib for Patients with Waldenström Macroglobulinemia

Registered drugNo placebo
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Acalabrutinib
  • Sponsor:Acerta Pharma B.V.

Study on the Effectiveness and Safety of Lazertinib and Gefitinib for Patients with Advanced or Metastatic Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Gefitinib
  • Sponsor:Yuhan Corp.

Multiple sclerosis

Not recruiting

Study on the Effectiveness and Safety of Fenebrutinib and Ocrelizumab for Adults with Primary Progressive Multiple Sclerosis

Registered drug
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Sponsor:F. Hoffmann-La Roche AG

Amyloidosis

Not recruiting

Study of Belantamab Mafodotin for Patients with Relapsed or Refractory AL Amyloidosis

InvestigationalNo placebo
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Belantamab Mafodotin
  • Sponsor:Emn Trial Office S.r.l. Impresa Sociale

Demyelination

Not recruiting

Study on the Effectiveness and Safety of Rozanolixizumab for Adults with Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOG-AD)

Registered drug
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Rozanolixizumab
  • Sponsor:UCB Biopharma

Other cities in Greece

The busiest research cities in the country

All 48 cities in Greece

Clinical research in Cholargos

What the registry says about research in the country

01 Lung Cancer Research

Comprehensive studies evaluating novel treatments for non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC), including investigations of targeted therapies and immunotherapy combinations.

  • Advanced treatment comparisons
  • Therapy combinations evaluation
  • Metastatic disease management

Research focuses on improving survival rates and treatment effectiveness for patients with various stages of lung cancer.

02 Breast Cancer Studies

Innovative clinical trials examining treatments for HER2-positive and estrogen receptor-positive breast cancer, with particular attention to early-stage and metastatic conditions.

  • Targeted therapeutic approaches
  • Hormone therapy evaluation
  • Recurrence prevention

Studies aim to enhance treatment outcomes and reduce recurrence risks in breast cancer patients.

03 Urological Cancers

Advanced research into bladder cancer and metastatic prostate cancer, exploring innovative combination therapies and novel treatment approaches.

  • Immunotherapy combinations
  • Treatment resistance studies
  • Novel drug evaluations

Trials focus on improving treatment outcomes for patients with advanced urological malignancies.

04 Gastrointestinal Oncology

Studies investigating treatments for advanced colorectal cancer, particularly focusing on specific genetic mutations and targeted therapies.

  • Mutation-specific treatments
  • Combination therapy assessment
  • Advanced disease management

Research aims to develop personalized treatment approaches based on genetic profiles.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.